Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8+T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma

Clinical and Translational Science

Volumn 1, Issue 3, 2008, Pages 228-239

  Leao, Ihid C ^b   Ganesan, Priya ^b   Armstrong, Todd D ^b   Jaffee, Elizabeth M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depletion; Mesothelin; Peptide identification; Tregulatory cells; Tumor therapy; Vaccination

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; EPITOPE; MESOTHELIN; MONOCLONAL ANTIBODY; PC 61; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LOW DRUG DOSE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LYMPHOCYTE DEPLETION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; VACCINATION;

MURINAE; MUS;

EID: 70350434889     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00070.x     Document Type: Article

References (46)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Nat!Acad Sci USA. 1996; 93: 136-140.
2. Robinson BW; Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362: 1612-1616.
3. Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Gin Cancer Res. 2004; 10: 3937-3942.
4. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther. 2008; 7: 286-296.
5. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothe I in-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004; 200: 297-306.
6. + regulatory T cells in cancer: Implications for immunotherapy. Microbes Infect. 2005; 7: 1056-1062.
7. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother. 2005; 54: 1153-1161.
8. + Tregs and immune control. J Gin Invest. 2004; 114: 1209-1217.
9. Shevach EM. Regulatory T cells: Introduction. Semin Immunol. 2004; 16: 69-71.
10. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003; 9: 606-612.
11. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002; 169: 2756-2761.
12. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949.
13. + immunoregulatory T cells: Central players in the arena of peripheral tolerance. Semin Immunol. 2004; 16: 81-88.
14. Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986; 46: 2572-2577
15. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JPH, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005; 201: 1591-1602.
16. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001; 61: 3689-3697
17. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999; 59: 3128-3133.
18. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163: 5211-5218.
19. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother. 2002; 25: 207-217
20. + regulatory T cells. J Exp Med. 2005; 202: 885-891.
21. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004; 34: 336-344.
22. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BIV6 mice. Cancer Res. 1984; 44: 717-726.
23. Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschluter M, Schneider Q Sauerbruch T, Schmidt-Wolf IGH. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003; 63: 8962-8967.
24. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J Exp Med. 1994; 179: 1215-1224.
25. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T cell epitope. Eur J Immunol. 1991; 21: 2891-2894.
26. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990; 346: 629-633.
27. Hudrisier D, Mazarguil H, Laval F, Oldstone MB, Gairin JE. Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications forpeptide selection and presentation. J Biol Chem. 1996; 271: 17829-17836.
28. Inaba K, Swiggard WJ, Steinman RM, Romani N, Sculer G. Current Protocols in Immunology. Mew York: Wiley; 1998.
29. + memory CTLs to become efficient effectors in vivo. J Immunol. 2004; 172 (6): 3719-3724.
30. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003; 21: 807-839.
31. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006; 90: 51-81.
32. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005; 5: 459-467
33. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008; 14 (5): 1455-1463.
34. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991; 351: 290-296.
35. Nagayama Y, Hase W, Motoyoshi Y, Saitoh O, Sogawa R, Nakao K. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effectorT cells. Oncol Rep. 2007; 17: 1269-1273.
36. Matsushita N, Pilon-Thomas SA, Martin LM, Riker Al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008; 333: 167-179.
37. + regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006; 13: 1252-1258.
38. Redmond WL, Wei CH, Kreuwel HT, Sherman LA. The apoptotic pathway contributing to the deletion of naive CD8 T cells during the induction of peripheral tolerance to a cross-presented self-antigen. J Immunol. 2008; 180: 5275-5282.
39. Hernandez J, Aung S, Marquardt K, Sherman LA. Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens. J Exp Med. 2002; 196: 323-333.
40. Kreuwel HT, Aung S, Silao C, Sherman LA. Memory CD8(+) T cells undergo peripheral tolerance. Immunity. 2002; 17: 73-81.
41. + T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J Immunol. 2005; 174: 3344-3351.
42. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005; 28: 120-128.
43. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. EurJ Immunol. 2004; 34: 2480-2488.
44. Depper JM, Leonard WJ, Drogula C, Kronke M, Waldmann TA, Greene WC. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc NatI Acad Sci USA. 1985; 82: 4230-4234.
45. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher Li, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LI. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001; 255: 27-40.
46. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, Kretzschmar I, Volkmer-Engert R, Volk HD, Reinke P. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000; 30: 1676-1682.